Apogee sold to Blackstone
Apogee Therapeutics agrees to $1.3 billion acquisition by Blackstone, sending shares higher. The deal is expected to expand Blackstone's presence in the biotech sector.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.